Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.

• DOI: 10.1200/jco.2023.41.16_suppl.9109
• Publication Date: 2023-06-04T16:16:25Z
• Authors: Makenzi Colleen E...; James Edward Butr...; John C. Paschold; Patrick J. Ward; Alexander I. Spira; Kashif Ali; Janet L. Espirito; David Hakimian; Robert M. Jotte; Beth Koselke; Timothy Larson; Michael W. Meshad; Marcus A. Neubauer; Katie Ogden; Rami Owera; Donald A. Richards; Nicholas J. Robert; Jennifer M. Walberg; Yunfei Wang; Robert L. Coleman
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

9109 Background: The MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Network) consortium pragmatic study aims to identify and overcome barriers timely appropriate biomarker testing patients (pts) with NSCLC. We previously reported retrospective real-world rates for 5 biomarkers from 2018-2020 metastatic pts. now report results the prospective observational phase, including additional pts both early advanced Methods: This was prospective, non-interventional cohort of newly diagnosed stage (ES), locally (LA), or NSCLC (mNSCLC) between 12/2020 9/2022 enrolled 12 community practices (69 sites) across US Oncology Network. proportion test 9 at time protocol initiation were examined: ALK, BRAF, EGFR, ROS1, PD-L1, KRAS, MET, NTRK, RET. Timing tests, use single vs multigene NGS testing, clinical socioeconomic factors, reasons not collected real time. Results: Of 1002 screened, 987 analyzed. There 405 IB-IIIC [n = 284 IB-IIIA (ES cohort); n 121 IIIB-IIIC (LA cohort)] 582 IV (mNSCLC cohort). Descriptions ES LA mNSCLC respectively include median age 68 69 yrs, 49% 52% female, 83% 77% white, 58% 79% adenocarcinoma histology, 71% 68% ECOG 0-1, 33% 30% high school education level. Testing cohorts are shown table below: prior treatment initiation, 64% had least one result; 37% all biomarkers. occurred 57% respectively. Reasons included: ordering (42%, 25%), insufficient tissue (18%, 18%), deterioration/crisis (5%, 12%), other (37%, 49%), Conclusions: As more genomic alterations identified NSCLC, we observed that many do get full genotyping treatment, remains utmost importance. Further analyses by distinct stages (e.g. LA), social determinants, utilization targeted therapies, will be performed. These data used evaluate future interventions MYLUNG, help improve comprehensive [Table: see text]